Propanc Biopharma reports pilot study shows anti — tumor efficacy for PRP proenzyme formulation in pancreatic, ovarian cancer
Propanc Biopharma reported results already presented in a newly published peer-reviewed pilot study in Scientific Reports on its PRP proenzyme therapy. Preclinical tests showed PRP slowed tumor growth and reduced spread-related behavior in pancreatic and ovarian cancer models, with tolerable safety. Separate UK Special